Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction
Launched by CENTRE FOR ADDICTION AND MENTAL HEALTH · Dec 20, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Eighty-eight adult inpatients completing residential treatment in the Addictions Services at the Centre for Addiction and Mental Health (CAMH) will be randomized to receive CBM-I daily for one week, adjunct to the residential psychosocial treatment or to an assessment-only control condition. Participants will complete clinical measures consisting of interviews and questionnaires measuring suicidal ideation, hopelessness, depression, negative affect, and interpretation biases before, during and after treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Exhibit moderate suicide risk or greater
- • Be enrolled in the Addictions Services inpatient program
- • Fluent in reading English
- • Capacity to give informed consent
- Exclusion Criteria:
- • A lifetime diagnosis of a psychotic or bipolar disorder
- • Significant neurological disorder or psychical illness likely to interfere with participation
- • Psychotropic medication changes within the past two weeks
About Centre For Addiction And Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada’s leading mental health and addiction teaching hospital, dedicated to advancing research, clinical care, and education in the field of mental health. With a commitment to improving the lives of individuals affected by mental illness and addiction, CAMH conducts innovative clinical trials aimed at developing and evaluating new treatment approaches. The institution fosters a collaborative environment that brings together researchers, clinicians, and community partners to translate scientific findings into effective interventions, ensuring the highest standards of care and support for patients. Through its robust research initiatives, CAMH strives to enhance understanding of mental health disorders and promote evidence-based practices in the treatment of addiction and mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Lena C Quilty, PhD
Principal Investigator
Centre for Addiction and Mental Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials